U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...
Most companies don't survive for decades, much less pay regular dividends for that long. Healthcare leaders Merck (NYSE: MRK) ...
Co's stock has reached a 52-week low, dipping to $85.71. This downturn reflects a significant shift from the previous year, with the pharmaceutical giant experiencing a 1-year change of -31.59%.
Chinese consumers, once the engine of growth for multinational companies, are cutting back on all kinds of things. Designer ...
The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...
The US Food and Drug Administration (FDA) has approved SpringWorks Therapeutics’ Gomekli (mirdametinib) to treat ...
The table below is a review of notable updates that occurred in January 2025 for investigational products in development.
The German drugmaker confirmed acquisition talks, but cautioned a deal may not materialize. Elsewhere, Biohaven got priority ...
We recently published an article titled Jim Cramer Discusses These 10 Stocks & An Outfit Better Than DeepSeek. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands ...
Artificial intelligence could be used to prescribe medications to patients — if a new bill makes its way through Congress ...
Following an initial report from Reuters, Merck KGaA confirmed that it is in talks with SpringWorks for a potential ...
As SpringWorks Therapeutics nears a key regulatory decision in the U.S., the Connecticut-based cancer and rare disease ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback